Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
Entrevista: Detectar el riesgo genético de padecer Alzheimer con un análisis de sangre
Hoy por Hoy - Cadena SER | Angels Barceló 27/01/2020
Detectar el riesgo genético de padecer Alzheimer con un análisis de sangre
SOCIEDAD / TERESA RUBIO - Cadena SER 27/01/2018 La empresa biotecnológica española Biocross ha desarrollado un test con el que, a través de una simple analítica de sangre, se puede averiguar el factor de riesgo genético de una persona a padecer Alzheimer. Este...
El SERGAS adjudica a Biocross un proyecto de compra de innovación tecnológica enfocado a soluciones en el campo del envejecimiento
El SERGAS ha adjudicado a Biocross S.L. el contrato de compra de innovación tecnológica para el desarrollo de servicios de I+D para el diagnóstico precoz en pacientes con patologías relacionadas con neurología, por un importe de 223.000€ dentro del plan de innovación...
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96